Weiyuan Synthesis Raises $41M for AI Bio-Manufacturing

Weiyuan Synthesis, a prominent player in China's synthetic biology sector, has successfully closed a 300 million yuan (approximately $41 million) Series A+ funding round. This significant capital infusion, finalized in March 2026, is earmarked to propel the company's advanced AI-driven biocomputation and biomanufacturing initiatives forward. The investment underscores the growing investor confidence in innovative biological solutions for industrial applications.

The funding round was spearheaded by the Henan Investment Group through its dedicated Hui Rong Fund. A notable participant was Tan Ruiqing, a seasoned investor with over three decades of experience in the chemical industry and a significant figure as a trustee of Fudan University and founder of the listed chemical enterprise, Longbai Group. His involvement brings substantial industry acumen and strategic depth to Weiyuan Synthesis.

Operating under the English trade name MicroCyto, the Henan-based firm leverages artificial intelligence and computational biology to tackle complex biomanufacturing hurdles. Its core technological strengths lie in AI-powered enzyme engineering, metabolic pathway optimization, and microbial strain development. This sophisticated approach has enabled the company to develop a proprietary one-step fermentation biotransformation process and cultivate expertise in creating highly efficient microbial strains. The company's diverse product pipeline targets critical sectors including human and animal nutrition, pharmaceuticals, personal care, agriculture, food, feed, and advanced materials.

Weiyuan Synthesis has already demonstrated its commercial viability by bringing several products to market, including allulose, a sought-after low-calorie sugar alternative, lutein, a potent carotenoid antioxidant, and mannitol, a versatile sugar alcohol utilized in food and pharmaceutical applications. A significant regulatory achievement was the company's receipt of administrative approval from China's National Health Commission in July 2025 for allulose production via biological fermentation, marking a first for any enterprise in the nation. This milestone, coupled with a strategic alliance formed in August 2025 with global agribusiness leader Cargill, highlights the company's robust technological platform and commercial readiness.

A key differentiator for Weiyuan Synthesis is its commitment to AI-driven biocomputation. The company's collaborative efforts with leading academic and technology institutions, including researchers from Stanford University, Princeton University, Peking University, ByteDance, and NVIDIA, led to the co-development of PoseX, an open-access platform for molecular docking evaluation. This initiative showcases the company's dedication to pushing the boundaries of computational biology and fostering open innovation.

The newly acquired capital will be strategically deployed to enhance AI biocomputing applications, accelerate research and commercialization of core technologies, expedite the industrialization of multiple product lines, and support the expansion of its Beidaihe production facility. This funding follows a substantial Series A round of nearly 300 million yuan completed in late 2025 or early 2026, which was led by the Beijing State-owned Investment Fund, further solidifying the company's growth trajectory in the rapidly evolving synthetic biology market.